Synopsis The role of dapagliflozin in inducing a favorable cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) is unknown. Since diabetes, atherosclerosis, and heart failure are all closely connected, it is of paramount importance that diabetic therapeutic interventions are also effective in reducing any cardiovascular risk in T2DM patients. This week’s “ MED FACT ” discusses a randomized, double-blind, multinational, placebo-controlled, phase 3 trial from the New England Journal of Medicine, ‘ Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes’ , Jan 2019.
Authors : Wiviott SD, Raz I, Bonaca MP , et al. Key Takeaways Dapagliflozin is beneficial in reducing the rate of hospitalization due to heart failure in T2DM patients with an existing or at an increased risk of atherosclerosis. Objective: To determine the efficacy of dapagliflozin, a selective…
